Drug intelligence / Profile preview

LP-123

Development stage: Unknown
Lead developer: Newave Pharmaceutical
Modality: Small Molecules

Overview

LP-123 is a small molecule antiviral candidate developed by Newave Pharmaceutical for the treatment of Hepatitis B Virus (HBV) infection. It is designed to target the Hepatitis B Virus antigen (HBVAg), aiming to disrupt the viral lifecycle or reduce the burden of viral proteins that contribute to immune evasion in chronic HBV patients. By targeting viral antigens, the drug potentially interferes with the maintenance of chronic infection and may help restore the host's immune response against the virus. As of the current pipeline status, LP-123 is in Phase 1 clinical development.

Beyond the preview

Go deeper on LP-123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-123.

Explore the full profile